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Abstract  
Objective 
 Primary graft failure (PGF) caused by ischemia-reperfusion injury (IRI), 
is the strongest determinant of perioperative mortality after heart 
transplantation. Atrial natriuretic peptide (ANP) has been found to reduce 
the IRI of cardiomyocytes and may be beneficial in alleviating PGF after 
heart transplantation, although there is a lack of evidence to support this 
issue. The purpose of this study was to investigate the cardioprotective 
effects of ANP after prolonged hypothermic storage. 
Methods 
An isolated working-heart rat model was used. After the preparation, the 
hearts were arrested with and stored in an extracellular-based cardioplegic 
solution at 3−4°C for 6 h and followed by 25min of reperfusion. The hearts 
were divided into 4 groups (n=7 each) according to the timing of ANP 
administration: group 1 (in perfusate before storage), group 2 (in 
cardioplegia), group 3 (in reperfusate), and control (no administration of 
ANP). Left ventricular functional recovery and the incidence of ventricular 
fibrillation (VF) was compared. 
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Results 
ANP administration at the time of reperfusion improved the percent 
recovery of left ventricular developed pressure (control,  45.5 ± 10.2;  
group 1, 47.4 ± 8.8; group 2, 45.3 ± 12 vs. group 3,  76.3 ± 7; p < 
0.05) and maximum first derivative of the left ventricular pressure (control, 
47.9 ± 8.7; group 1, 46.7 ± 8.8; group 2, 49.6 ± 10.8 vs. group 3, 
76.6 ± 7.5; p < 0.05). The incidence of VF after reperfusion did not differ 
significantly among these 4 groups (71.4%, 85.7%, 57.1%, and 85.7% in 
groups 1, 2, 3, and control, respectively). 
 
Conclusions 
 Administration of ANP at the time of reperfusion significantly improves 
the recovery of left ventricular function after prolonged hypothermic 
ischemia and may have the potential to decrease the incidence of PGF after 
heart transplantation.  
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Introduction 
 Primary graft failure (PGF) is the strongest determinant of perioperative 
mortality after heart transplantation, and is responsible for up to 42% of 
perioperative deaths (1). Acute ischemia-reperfusion injury (IRI) with 
myocardial stunning has been proposed to be a predominant factor in the 
development of PGF (2). Most donor hearts are stored in a cold 
preservation solution and transported on ice. Hypothermic storage slows 
but does not completely arrest cellular metabolism. Consequently, 
progressive ischemic injury is an inevitable consequence of prolonged 
storage.  
 IRI involves damage to cardiomyocytes, vascular smooth muscle, and 
endothelial cells. When cardiomyocytes are reoxygenated after a prolonged 
period of energy depletion, severe cytosolic calcium overload and 
reactivation of energy production results in deleterious hypercontracture, 
which leads to cell disruption in tissue (3). Recent experimental studies 
have demonstrated that reoxygenation-induced hypercontracture can be 
prevented if the contractile apparatus is temporarily blocked during the 
initial phase of reoxygenation to reestablish normal cytosolic calcium 
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control (4). 
 Myocardial guanosine 3', 5'-cyclic monophosphate (cGMP), which 
reduces the calcium sensitivity of myofilaments (5), is reduced in 
myocardial cells after prolonged ischemia (6). The stimulation of cGMP 
synthesis at the time of reoxygenation has an inhibitory contractile effect in 
reperfused myocardium, and is able to prevent reoxygenation-induced 
hypercontracture in isolated cardiomyocytes (7), isolated hearts (6), and in 
situ hearts (8). 
Atrial natriuretic peptide (ANP) is known to stimulate the synthesis of the 
particulate guanylate cyclase, causing a consequent increase in cGMP 
synthesis. Thus, it is able to protect the myocardium against IRI and can 
preserve myocardial function. 
 Based on these findings, it seems likely that ANP could be beneficial in 
ameliorating PGF in a transplanted heart. Although there is evidence that 
ANP can have a cardioprotective effect in acute myocardial infarction (9, 
10, 11) or cardiac surgery (12), its potential role in heart transplantation has 
not yet been investigated. Therefore, we investigated the ability of ANP to 
improve the functional recovery of isolated working rat hearts after 
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prolonged hypothermic storage in an extracellular-based cardioplegic 
solution. 
 
Materials and Methods 
 
Animals 
 Male Sprague-Dawley rats were used in the present study. All animals 
received humane care in compliance with the “Guide for the Care and Use 
of Laboratory Animals” published by the US National Institute of Health 
(National Institutes of Health publication No. 85-23, revised 1996). The 
experimental protocol was approved by the Experimental Animals 
Committee of the Okayama University School of Medicine. 
 
Isolated rat heart model 
The composition of the modified Krebs-Henseleit bicarbonate buffer 
(KHB) used for organ perfusion was as follows (in mmol/L): NaCl, 118.0; 
NaHCO3, 25.0; CaCl2, 2.5; MgSO4, 1.2; KCl, 4.7; KH2PO4, 1.2; and 
glucose, 11. The pH was 7.4. The KHB was bubbled with 95% oxygen and 
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5% carbon dioxide gas at 38.0°C to maintain an aortic partial oxygen 
pressure of >400 mmHg. It was filtered through a cellulose acetate 
membrane (pore size 0.45 µm) to remove any particulate contaminants. 
 The composition of the extracellular-based cardioplegic solution was as 
follows ( in mmol/L): Na
+
, 142.0; K
+
, 18.5; Mg
2+
, 18.5; Ca
2+
, 1.1; HCO3
-
, 
1.9; and glucose, 11.1. 
 We modified and used an isolated, perfused, rat heart apparatus that was 
previously described by Fujii and associates (13). This circuit was designed 
to work in 2 interchangeable conditions, namely the unloaded and loaded 
modes. In the unloaded mode, the hearts were perfused through the aorta at 
a pressure of 80 cmH2O and continued to beat without external work. In the 
loaded mode, the hearts were perfused in the same fashion, but beat against 
external force. These hearts were not paced and the coronary effluent was 
discarded.  
The rats were anesthetized with an intraperitoneal injection of 
pentobarbital (50mg/kg), and heparin (100 IU/100g body weight) was 
injected into the exposed right femoral vein. The hearts were quickly 
excised and immersed in cold (4°C) modified KHB, and Langendorff 
 8 
perfusion was establishied. The aorta was cannulated within 1 min after the 
excision. The pulmonary artery was incised to facilitate coronary drainage. 
The heart was then perfused in a retrograde manner under the perfusion 
conditions of the unloaded mode at 38.0°C for 10 min. Subsequently, the 
changes in heart rate (HR), left ventricular developed pressure (LVDP), and 
the first derivative of LV pressure (dp/dt max) were monitored under the 
loaded mode with commercially available software (PowerLab, 
ADInstruments, Sydney, Australia) using an intraventricular balloon 
inserted through the mitral annulus that was inflated with distilled water. 
During the pressure measurement, the left ventricular end-diastolic pressure 
was maintained at 4 mmHg using the intraventricular balloon. The 
coronary flow (CF) was measured by direct collection of coronary effluent 
dripping from the heart for 1 min. 
 
Study protocol 
 The study protocol is shown in Figure 1. Hearts were perfused in the 
unloaded mode for 10 min followed by the loaded mode for 15 min. During 
the later interval, we measured the baseline value of HR, LVDP, and dp/dt 
 9 
max. The cardioplegic solution (at 3−4°C) was then infused into the 
coronary circulation for 1 min from a reservoir located 80 cm above the 
heart and the hearts were stored on ice (3−4°C) in 100 mL of the same 
cardioplegic solution for 6 h. At the end of this period, the hearts were 
remounted on the perfusion apparatus and reperfused in the unloaded mode 
for 10 min. The apparatus was then switched to the loaded mode and we 
recorded the aforementioned indices of cardiac function at 1, 5, 10, and 
15min. Data beyond 15 min were not recorded because we observed no 
further recovery beyond 15 min. The recovery of each parameter was 
expressed as a percentage of its pre-storage value.  
The CF and its cGMP concentration were also measured before storage, 
and at 1 and 15 min of the post-reperfusion loaded mode.  
The hearts were removed from the apparatus at the end of the experiment. 
They were heated to 70°C for 14 days, and were then weighed to determine 
the dry weight of ventricular myocardium. The concentration of cGMP was 
determined by radioimmunoassay as previously described (14) and was 
expressed in pmol/g dry weight per min. 
 We also noted the incidence of ventricular fibrillation (VF) at the time of 
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reperfusion. 
The rats were divided into 4 groups (n = 7 in each group). The control 
hearts were perfused with KHB. To determine the optimal timing for ANP 
administration, we added ANP (alpha-human atrionatriuretic peptide; 
Sankyo-Daiichi, Tokyo, Japan) to the perfusate before storage (Group 1), to 
the cardioplegic solution (Group 2), or to the perfusate during reperfusion 
(Group 3), using a dose of 0.1 μmol/L. It has been reported that 
administration of 0.1 μmol/L ANP induces a threefold increase in cGMP 
release into the coronary effluent without any effect on cardiac function in 
the isolated rat heart (15). 
 
Exclusion 
 At the first hemodynamic evaluation, hearts beating at a rate less than 
250beats/min were considered to have experienced myocardial damage 
during the preparation. These hearts were excluded from the study. 
 
Statistical analysis 
 All data were expressed as mean ± standard deviation. The statistical 
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analysis was performed using commercially available software (SPSS for 
Windows; SPSS Japan, Tokyo, Japan). Differences among multiple groups 
were determined using one-way analysis of variance followed by Scheffe’s 
test. The incidence of VF among groups was compared using the chi-square 
test. A p-value of <0.05 was regarded as statistically significant. 
 
Results 
  
Pre-ischemic data 
 Table 1 shows the body weight of the rats, HR, CF, dp/dt max, LVDP, and 
cGMP release in the coronary effluent during the pre-ischemic loaded 
perfusion. There were no statistically significant differences in HR, CF, 
dp/dt max, and LVDP. Only group 1 had a higher release of cGMP in the 
coronary drainage induced by the administration of ANP. 
 
Post-ischemic cardiac functional recovery and changes in cGMP 
 The post-ischemic recovery of HR, dp/dt max, and LVDP was expressed 
as a percentage of the pre-ischemic value; the results are listed in Figure 2. 
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The recovery of LVDP and dp/dt max was better in group 3, than in the 
other groups ( LVDP: control, 45.5 ± 10.2; group 1, 47.4 ±  8.8;  
group 2, 45.3 ± 12; vs. group 3, 76.3 ± 7; p < 0.05. dp/dt max: control,  
47.9 ± 8.7; group 1, 46.7 ± 8.8; group 2, 49.6 ± 10.8; vs. group 3, 
76.6 ± 7.5; p < 0.05). There was no difference in the recovery of HR 
(control, 82 ± 4.7; group 1, 90.3 ± 7.4, group 2, 87.8 ± 7.6; group 3,  
89 ± 11.2).  
The cGMP release into the CF increased after ischemia only in group 3 
(control, 1.31 ± 0.23; group 1, 1.35 ± 0.15; group 2, 1.26 ± 0.28; vs. 
group 3, 5.32 ± 1.63; p < 0.05). There was no difference in the post 
ischemic recovery of CF (control, 79.7 ± 20.1; group 1, 85.6 ± 9.5; 
group 2, 78 ± 10.6;  group 3,  83.6 ± 11). 
 The post-ischemic cardiac functional recovery was closely related to the 
significantly increased cGMP release due to the infusion of ANP at the time 
of reperfusion. 
 
Incidence of ventricular fibrillation after reperfusion 
 The occurrence of VF after reperfusion was noted in 6 (85.7%), 5 (71.4%), 
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6 (85.7%), and 4 (57.1%) rats in the control group, group 1, group 2, and 
group 3, respectively. There was no significant difference among these 
groups (p = 0.552).  
 
Discussion 
The present study showed that the administration of ANP at the time of 
reperfusion elicited a significant improvement in the acute-phase 
post-ischemic recovery of left ventricular function after 6 h of hypothermic 
storage of the rat heart. This improvement was attributed to the increased 
cGMP release triggered by ANP, as demonstrated by previous investigators 
(11, 15). In contrast, the administration of ANP before ischemia or during 
cardioplegia was not associated with any significant improvement in the 
recovery of left ventricular function after reperfusion.  
The timing of treatment aimed at increasing cGMP release for protection 
against hypoxia-reoxygenation or IRI has been controversial. Okawa and 
colleagues (16) reported that pre-ischemic infusion of ANP elicits 
myoprotective effects during ischemia reperfusion in isolated rat hearts. 
Agulló and colleagues (17) reported that L-arginine supplementation before 
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hypoxia increases cGMP release during reoxygenation and improves 
functional recovery in isolated rat hearts subjected to 40 min of hypoxia. 
Recent ischemia-reperfusion studies (6, 11) have demonstrated that 
urodilatin, a member of the natriuretic peptide family, improves functional 
recovery when administered at the time of reperfusion. Sangawa and 
colleagues (15) also reported that the administration of ANP at the time of 
reperfusion after 15 min of normothermic global ischemia, improved 
post-ischemic recovery; however, no improvement was observed when 
ANP was administered before ischemia. All of these studies were 
performed under conditions of acute ischemic heart disease or resuscitation 
from sudden cardiac arrest; therefore, the ischemic times ranged from only 
15 to 60 min. 
Besides promoting the synthesis of cGMP, ANP also appears to have an 
additional cardioprotective effect against IRI in the myocardium. An 
experimental study has presented evidence for the presence of an 
independently functioning and local renin-angiotensin system in the heart 
(18). In an isolated perfused rat heart, angiotensin ІІ was found to 
exacerbate ischemia-induced ventricular fibrillation and impaired 
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cardiodynamics, whereas these effects were blocked by ANP (19). Morales 
et al. (20) reported that the direct blocking of the local renin-angiotensin 
system with angiotensin ІІ receptor antagonists ameliorates myocardial 
stunning after global ischemia. Therefore, the functional antagonism of 
angiotensin ІІ may underlie the protective effect of ANP against IRI. 
Reperfusion-induced arrhythmia is one of the important factor for IRI. 
Several mechanisms are believed to be responsible for the development of 
reperfusion-induced arrhythmia. One of the important mechanisms is 
considered to be intercellular Ca
2+
 overload, caused by an involvement of 
H
+
/Na
+
 and Na
+
/Ca
2+
 exchange (21, 22). The effect of ANP on 
reperfusion-induced arrhythmia remains unclear. Takata et al (23) reported 
that, in anesthetized dogs subjected to 30 min of left circumflex artery 
occlusion followed by 60 min of reperfusion, ANP infusion inhibited 
reperfusion-induced ventricular arrhythmias and preserved the high-energy 
phosphate content in the inner layer of the ischemic myocardium. The 
authors suggested that the beneficial effects of ANP were probably due to 
its direct effects via cGMP as a stimulator of Na
+
/Ca
2+
 exchange, leading to 
a reduction of intracellular Ca
2+
 overload. However, 2 other reports failed 
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to detect any favorable effect on ventricular arrhythmias after coronary 
occlusion in dogs (9), or during reperfusion in the isolated rat heart after 30 
min of regional ischemia (24). In the present study, the administration of 
ANP at the time of reperfusion did not prevent VF. However, as our 
findings indicated that ANP might reduce reperfusion-induced arrhythmia, 
we increased the number of rats to 13 in both the control group and group 3, 
as a complementary study to determine whether or not a significant 
difference in the incidence of VF would be observed. We noted that 12 of 
13 rats (92%) in the control group and 8 of 13 rats (62%) in group 3 
exhibited VF at the time of reperfusion. The incidence of VF tended to be 
lower in group 3 than in the control group, but the difference was not 
statistically significant (p = 0.062). The reason for the disparity between the 
results of different studies regarding the beneficial effect of ANP on 
reperfusion-induced arrhythmias is unclear. Differences in the experimental 
protocol (i.e., the duration of the ischemic periods, the dose of ANP, or the 
extent of the ischemia) might have affected the results. We believe that 
further investigation is required to confirm the effect of ANP on 
reperfusion-induced arrhythmias. 
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Despite the improvements in the treatment of PGF, it is still associated 
with high morbidity and mortality (2), and is the most common cause of 
death within the first month after heart transplantation. It has been reported 
that a prolonged total graft ischemic time, accelerating IRI is one of the risk 
factors for PGF (25, 26). But, because of the shortage of donor hearts, the 
use of marginal hearts that have a prolonged ischemic time may increase 
the likelihood of PGF. Thus, investigation of the safe storage of donor 
hearts and the preservation of their ventricular function is becoming 
increasingly important. The excellent recovery of left ventricular function 
after 6 h of cold ischemic arrest in the present study indicates that ANP 
may have a preventive effect against PGF after heart transplantation. 
 
 Limitations of the model 
 There are several limitations to our study. First, we did not use the heart 
transplant model to evaluate the cardiac function of the rat heart. Therefore, 
it might be difficult to extrapolate the results directly to heart plantation. 
Second, we did not confirm a cause and effect relationship between cGMP 
and postischemic recovery by using cGMP analogs and antagonists. 
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However, previous studies using isolated rat heart models demonstrated 
that improved functional recovery, induced by the administration of the 
natriuretic peptide urodilatin during initial reperfusion after 40 min of 
ischemia, was reproduced by the cGMP analog 8-bromo-cGMP (6), and 
that reduction in lactate dehydrogenase release by urodilatin after 60 min of 
ischemia was abolished by adding the ANP receptor antagonist isatin (11). 
Third, we used an isolated perfused preparation. Although the preparations 
were denervated, direct cardiac responses can be studied independently of 
the systemic effects of ANP. Finally, we used a crystalloid solution in the 
perfusion circuit. Blood perfusion may induce different results from those 
of crystalloid perfusion (27). Because each blood component serves 
different roles during ischemia and reperfusion and might affect the results, 
we used a simple crystalloid solution in this study. 
 
Conclusion 
 The administration of ANP at the time of reperfusion after prolonged 
hypothermic storage significantly improved left ventricular function after 
reperfusion, although it did not significantly reduce the incidence of VF. 
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ANP may be a beneficial adjunct to improve the ventricular function of a 
donor heart as a means of decreasing the incidence of PGF during heart 
transplantation. 
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BW(g) LVDP(mmHg)
d p/dt max
(mmHg/sec)
HR(beat/min) CF(mL/min)
cGMP
(pmol/dry weight/min) 
control 275±21.5 132.2±9.1 3811.4±378.6 279.3±19.7 9.5±2 1.54±0.25
group 1 272.7±18.9 127±9.2 3879±410 298±21 10.1±1.2 4.46±0.98 *
group 2 282.3±22.9 128.6±6.5 3965.1±530.9 290.7±23.8 10.4±1.4 1.45±0.32
group 3 272.9±4.6 135.6±9.3 3936.3±549.3 291.7±24.7 8.4±1.2 1.42±0.24
* P<0.05  group1 vs control, group 2, group 3
Table 1.  Pre-ischemic data
 
Values are presented as mean ± standard deviation. BW, body weight; 
LVDP, left ventricular developed pressure; dp/dt max, first derivate of left 
ventricular pressure; HR, heart rate; CF coronary flow; cGMP, cyclic 
guanosine monophosphate 
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Control
Group 1
Group 2
Group 3
U L U LStorage
10min 15min 10min 15min6 hours
Pre-Storage Reperfusion
Perfusate
Perfusate+ANP
Perfusate
Perfusate
CP
CP
CP + ANP
CP
Baseline 1   5    10    15min
Figure 1. Experimental protocol
Hemodynamic measurement
Perfusate
Perfusate
Perfusate
Perfusate+ANP
 
U, Unloaded perfusion; L, Loaded perfusion; ANP, atrial natriuretic 
peptide; CP, Cardioplegia 
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* P<0.05  group 3 vs.  control, group 1, group 2
Figure 2.  
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The postischemic recovery of the first derivative of left ventricular pressure 
(dp/dt max), heart rate (HR), and the left ventricular developed pressure 
(LVDP). The recovery of dp/dt max and LVDP was better in Group 3. 
 
